Travere Therapeutics Enters Into Exclusive Licensing Agreement with Everest Medicines for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases View Full Press Release Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)